VERAXA Biotech AG (NASDAQ: VRXA), a company focused on next-generation antibody-based cancer therapies, has announced new in vitro proof-of-concept data supporting its BiTAC-ADC technology. The data, released ahead of the BIO International Convention 2026 in San Diego (https://nnw.fm/APy2D), demonstrate that the platform can selectively target cancer cells while sparing healthy cells in early laboratory studies.
The company’s BiTAC (Bispecific T-cell Activating Complex) approach is designed to improve the precision of antibody-based therapies by activating therapeutic effects only in tumor cells. The new data showed that the BiTAC-ADC platform distinguished between breast cancer cells and healthy cells and produced dose-dependent destruction of three-dimensional tumor cell spheroids. While the technology is still in early development, these results mark a step forward in addressing a key challenge in oncology: minimizing off-target toxicity.
VERAXA maintains a diversified pipeline of antibody-based formats, including antibody-drug conjugates (ADCs), T-cell engagers (TCEs), and other antibody-based formats. The company plans to present both its BiTAC-ADC and BiTAC-TCE platforms for potential strategic collaborations at the upcoming BIO convention, signaling its intent to partner with pharmaceutical and biotechnology companies to further develop these technologies.
The announcement comes shortly after VERAXA began trading on the NASDAQ Capital Market under the ticker VRXA, following the completion of its business combination with Voyager Acquisition Corp. This listing provides the company with access to capital markets to support its research and development efforts.
The implications of these data are significant for the field of cancer therapy. ADCs are a powerful class of drugs that deliver cytotoxic payloads directly to cancer cells, but their use is often limited by damage to healthy tissue. VERAXA’s BiTAC-ADC platform aims to overcome this limitation by ensuring the therapeutic effect is activated only in the tumor microenvironment. If validated in further preclinical and clinical studies, this could lead to safer and more effective treatments for patients.
For investors, the company’s progress provides a glimpse into the potential value of its technology. However, as with all early-stage biotech developments, significant hurdles remain, including the need for in vivo testing and eventual human trials. The company’s newsroom (https://nnw.fm/VRXA) will continue to provide updates as the pipeline advances.
VERAXA’s focus on precision and selectivity aligns with broader trends in oncology toward personalized medicine and reduced side effects. The success of its BiTAC platform could position the company as a key player in the next wave of antibody-based cancer therapies.
